Katarzyna Kamińska1, Anna M Czarnecka2, Bernard Escudier3, Fei Lian4, Cezary Szczylik2. 1. Department of Oncology, Military Institute of Medicine, Warsaw, Poland. Electronic address: kaminska-katarzyna@hotmail.com. 2. Department of Oncology, Military Institute of Medicine, Warsaw, Poland. 3. Medical Oncology Department, Institut Gustave Roussy, Villejuif, France. 4. Emory University School of Medicine, Atlanta, GA.
Abstract
BACKGROUND: Our knowledge on the molecular basis of kidney cancer metastasisis still relatively low. About 25-30% of patients suffering from clear cell renal cell carcinoma (ccRCC)present metastatic disease at the time of primary diagnosis. Only 10% of patients diagnosed with stage IV disease survive 5 years and 20-50% of patients diagnosed with localized tumor develop metastases within 3 years. High mortality of patients with this cancer is associated with a large potential for metastasis and resistance to oncologic treatments such as chemo- and radiotherapy. Literature data based on studies conducted on other types of cancers suggest that in metastatic ccRCC, the complex of interleukin-6 (IL-6) and its soluble receptor (sIL-6R; complex IL-6/sIL-6R) and the signal transduction pathway (gp130/STAT3) might play a key role in this process. PURPOSE: Therefore, in this review we focus on the role of IL-6 and its signaling pathways as a factor for development and spread of RCC. Analyzing the molecular basis of cancer spreading will enable the development of prognostic tests, evaluate individual predisposition for metastasis, and produce drugs that target metastases. As the development of effective systemic treatments evolve from advancements in molecular biology, continued studies directed at understanding the genetic and molecular complexities of this disease are critical to improve RCC treatment options.
BACKGROUND: Our knowledge on the molecular basis of kidney cancer metastasisis still relatively low. About 25-30% of patients suffering from clear cell renal cell carcinoma (ccRCC)present metastatic disease at the time of primary diagnosis. Only 10% of patients diagnosed with stage IV disease survive 5 years and 20-50% of patients diagnosed with localized tumor develop metastases within 3 years. High mortality of patients with this cancer is associated with a large potential for metastasis and resistance to oncologic treatments such as chemo- and radiotherapy. Literature data based on studies conducted on other types of cancers suggest that in metastatic ccRCC, the complex of interleukin-6 (IL-6) and its soluble receptor (sIL-6R; complex IL-6/sIL-6R) and the signal transduction pathway (gp130/STAT3) might play a key role in this process. PURPOSE: Therefore, in this review we focus on the role of IL-6 and its signaling pathways as a factor for development and spread of RCC. Analyzing the molecular basis of cancer spreading will enable the development of prognostic tests, evaluate individual predisposition for metastasis, and produce drugs that target metastases. As the development of effective systemic treatments evolve from advancements in molecular biology, continued studies directed at understanding the genetic and molecular complexities of this disease are critical to improve RCC treatment options.
Authors: Kunyu Shen; David W Johnson; David A Vesey; Michael A McGuckin; Glenda C Gobe Journal: Cell Stress Chaperones Date: 2017-09-27 Impact factor: 3.667
Authors: Katarzyna Kaminska; Anna M Czarnecka; Mohammed Imran Khan; Wojciech Fendler; Aleksandra Klemba; Pawel Krasowski; Ewa Bartnik; Cezary Szczylik Journal: Int J Oncol Date: 2017-12-29 Impact factor: 5.650
Authors: Martin Pilskog; Leif Bostad; Reidunn J Edelmann; Lars A Akslen; Christian Beisland; Oddbjørn Straume Journal: J Pathol Clin Res Date: 2018-03-05
Authors: Pierre Bigot; Leandro M Colli; Mitchell J Machiela; Lea Jessop; Timothy A Myers; Julie Carrouget; Sarah Wagner; David Roberson; Caroline Eymerit; Daniel Henrion; Stephen J Chanock Journal: Nat Commun Date: 2016-07-07 Impact factor: 14.919